Autologous and allogenic systems of HIV expansion: what is the better choice for clinical application in therapeutic vaccine?

Nenhuma Miniatura disponível
Citações na Scopus
1
Tipo de produção
article
Data de publicação
2013
Título da Revista
ISSN da Revista
Título do Volume
Editora
FUTURE MEDICINE LTD
Citação
IMMUNOTHERAPY, v.5, n.12, p.1305-1311, 2013
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Aims: HIV-1 expanded in an allogenic system (Al-HIV) represents a cheaper and faster alternative to the autologous virus (Au-HIV) as an antigen in anti-HIV immunotherapy. In this study, chemically inactivated HIV-1 obtained through autologous or allogenic systems were compared. Patients & methods: Au-HIV and Al-HIV obtained from cultures of peripheral blood mononuclear cells from 11 HIV+ individuals were tested for virus production, yield and time of culture, and their ability to elicit a specific immune response in vitro. Results: The allogenic system was more efficient than the autologous system. Dendritic cells pulsed with Au-HIV and Al-HIV presented a similar phenotypic profile, but only Al-HIV induced a significant increase in IFN-(+) lymphocytes. Conclusion: The use of an allogenic system displays several advantages in terms of cell manipulation, time and cost of culture, and immunogenicity.
Palavras-chave
autologous HIV, dendritic cell, therapeutic vaccine, virus production
Referências
  1. Brenchley JM, 2006, NAT MED, V12, P1365, DOI 10.1038/nm1511
  2. Connolly NC, 2008, CLIN VACCINE IMMUNOL, V15, P284, DOI 10.1128/CVI.00221-07
  3. Garcia F, 2005, J INFECT DIS, V191, P1680, DOI 10.1086/429340
  4. Garcia F, 2013, SCI TRANSL MED, V5
  5. Garcia F, 2011, J INFECT DIS, V203, P473, DOI 10.1093/infdis/jiq077
  6. Gil C, 2011, VACCINE, V29, P5711, DOI 10.1016/j.vaccine.2011.05.096
  7. Kundu SK, 1998, AIDS RES HUM RETROV, V14, P551, DOI 10.1089/aid.1998.14.551
  8. Lu W, 2004, NAT MED, V10, P1359, DOI 10.1038/nm1147
  9. Rossio JL, 1998, J VIROL, V72, P7992
  10. Sabado RL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004256
  11. Whiteside TL, 2009, CLIN VACCINE IMMUNOL, V16, P233, DOI 10.1128/CVI.00066-08
  12. WHO, 2002, WHO UNAIDS GUID STAN